JP2022505989A5 - - Google Patents

Info

Publication number
JP2022505989A5
JP2022505989A5 JP2021523159A JP2021523159A JP2022505989A5 JP 2022505989 A5 JP2022505989 A5 JP 2022505989A5 JP 2021523159 A JP2021523159 A JP 2021523159A JP 2021523159 A JP2021523159 A JP 2021523159A JP 2022505989 A5 JP2022505989 A5 JP 2022505989A5
Authority
JP
Japan
Prior art keywords
compound
salt according
salt
inhibitors
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523159A
Other languages
English (en)
Japanese (ja)
Other versions
JP7526174B2 (ja
JP2022505989A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059238 external-priority patent/WO2020089778A1/en
Publication of JP2022505989A publication Critical patent/JP2022505989A/ja
Publication of JP2022505989A5 publication Critical patent/JP2022505989A5/ja
Application granted granted Critical
Publication of JP7526174B2 publication Critical patent/JP7526174B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523159A 2018-10-29 2019-10-28 キナゾリニル-インダゾール誘導体及びそのヒト免疫不全ウイルス複製の阻害剤としてのその使用 Active JP7526174B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751733P 2018-10-29 2018-10-29
US62/751,733 2018-10-29
PCT/IB2019/059238 WO2020089778A1 (en) 2018-10-29 2019-10-28 Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication

Publications (3)

Publication Number Publication Date
JP2022505989A JP2022505989A (ja) 2022-01-14
JP2022505989A5 true JP2022505989A5 (cg-RX-API-DMAC7.html) 2022-11-04
JP7526174B2 JP7526174B2 (ja) 2024-07-31

Family

ID=68425185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523159A Active JP7526174B2 (ja) 2018-10-29 2019-10-28 キナゾリニル-インダゾール誘導体及びそのヒト免疫不全ウイルス複製の阻害剤としてのその使用

Country Status (5)

Country Link
US (1) US20210403465A1 (cg-RX-API-DMAC7.html)
EP (1) EP3873607B1 (cg-RX-API-DMAC7.html)
JP (1) JP7526174B2 (cg-RX-API-DMAC7.html)
ES (1) ES2969030T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020089778A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53973A (fr) 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
JP2022506399A (ja) * 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
US12564595B2 (en) 2019-11-28 2026-03-03 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent
WO2021176366A1 (en) * 2020-03-06 2021-09-10 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US12703699B2 (en) 2020-03-06 2026-08-11 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
CN111548349A (zh) * 2020-05-13 2020-08-18 厦门云凡医药科技有限公司 一种ret激酶抑制剂中间体及其制备方法
TW202448483A (zh) * 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
US9873680B2 (en) 2014-08-29 2018-01-23 Gilead Sciences, Inc. Therapeutic compounds
LT3347352T (lt) 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
JP7361766B2 (ja) 2018-09-14 2023-10-16 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
WO2020058844A1 (en) * 2018-09-20 2020-03-26 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2020084491A1 (en) 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
PT3870575T (pt) 2018-10-25 2023-05-12 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
US20210395248A1 (en) 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP2022506399A (ja) 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤

Similar Documents

Publication Publication Date Title
JP2022505597A5 (cg-RX-API-DMAC7.html)
JP2022505841A5 (cg-RX-API-DMAC7.html)
JP2022500425A5 (cg-RX-API-DMAC7.html)
JP2022505637A5 (cg-RX-API-DMAC7.html)
JP2022501370A5 (cg-RX-API-DMAC7.html)
JP2003503385A5 (cg-RX-API-DMAC7.html)
JP2017537126A5 (cg-RX-API-DMAC7.html)
JP2012525393A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2024173998A5 (cg-RX-API-DMAC7.html)
JP2020512337A5 (cg-RX-API-DMAC7.html)
JP2006506425A5 (cg-RX-API-DMAC7.html)
JP2019522024A5 (cg-RX-API-DMAC7.html)
BRPI0715492A2 (pt) uso de inibidores diretos de trombina
JP2021530513A5 (cg-RX-API-DMAC7.html)
JP2008534453A5 (cg-RX-API-DMAC7.html)
JP2008508214A (ja) 女性の性障害の治療用ピペラジン誘導体
JP2022537047A5 (cg-RX-API-DMAC7.html)
JP2004517843A5 (cg-RX-API-DMAC7.html)
RU99101081A (ru) Режим введения ингибиторов н+, к+-атфазы
RU2009148507A (ru) Производное тетрагидроизохинолин-1-она или его соль
JP2021520400A (ja) エダラボン医薬組成物
JP2022531251A5 (cg-RX-API-DMAC7.html)
JP2019528279A5 (cg-RX-API-DMAC7.html)
JP2025508656A5 (cg-RX-API-DMAC7.html)